274 related articles for article (PubMed ID: 30974033)
41. GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials.
Cao C; Yang S; Zhou Z
Endocrine; 2019 Nov; 66(2):157-165. PubMed ID: 31420784
[TBL] [Abstract][Full Text] [Related]
42. GLP-1 receptor agonists do not affect sodium intake: Exploratory analyses from two randomized clinical trials.
Smits MM; Ten Kulve JS; van Bloemendaal L; Tonneijck L; Muskiet MHA; Kramer MHH; Ijzerman RG; van Raalte DH
Nutrition; 2019; 67-68():110524. PubMed ID: 31415908
[TBL] [Abstract][Full Text] [Related]
43. Glucagon-Like Peptide 1 (GLP-1) Receptor Variants and Glycemic Response to Liraglutide: A Pharmacogenetics Study in Iranian People with Type 2 Diabetes Mellitus.
Eghbali M; Alaei-Shahmiri F; Hashemi-Madani N; Emami Z; Mostafavi L; Malek M; Khamseh ME
Adv Ther; 2024 Feb; 41(2):826-836. PubMed ID: 38172377
[TBL] [Abstract][Full Text] [Related]
44. Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis.
Tang H; Li G; Zhao Y; Wang F; Gower EW; Shi L; Wang T
Diabetes Obes Metab; 2018 May; 20(5):1262-1279. PubMed ID: 29369494
[TBL] [Abstract][Full Text] [Related]
45. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
Gentilella R; Pechtner V; Corcos A; Consoli A
Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747
[TBL] [Abstract][Full Text] [Related]
46. Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Intima-Media Thickness: Systematic Review and Meta-Analysis.
Akbari A; Hadizadeh S; Heidary L
J Diabetes Res; 2024; 2024():3212795. PubMed ID: 38529046
[TBL] [Abstract][Full Text] [Related]
47. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
Ji Q
Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
[TBL] [Abstract][Full Text] [Related]
48. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials.
Monami M; Cremasco F; Lamanna C; Colombi C; Desideri CM; Iacomelli I; Marchionni N; Mannucci E
Exp Diabetes Res; 2011; 2011():215764. PubMed ID: 21584276
[TBL] [Abstract][Full Text] [Related]
49. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.
Tonneijck L; Muskiet MHA; Smits MM; Bjornstad P; Kramer MHH; Diamant M; Hoorn EJ; Joles JA; van Raalte DH
Diabetes Obes Metab; 2018 May; 20(5):1235-1245. PubMed ID: 29341461
[TBL] [Abstract][Full Text] [Related]
50. Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review.
Guo X; Yang Q; Dong J; Liao L; Zhang W; Liu F
Clin Drug Investig; 2016 Jun; 36(6):433-41. PubMed ID: 26979594
[TBL] [Abstract][Full Text] [Related]
51. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.
Edelman SV
J Fam Pract; 2017 Oct; 66(10 Suppl):S12-S16. PubMed ID: 28991932
[TBL] [Abstract][Full Text] [Related]
52. Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes.
Storgaard H; Cold F; Gluud LL; Vilsbøll T; Knop FK
Diabetes Obes Metab; 2017 Jun; 19(6):906-908. PubMed ID: 28105738
[TBL] [Abstract][Full Text] [Related]
53. [Effects of GLP-1 receptor agonists on carbohydrate metabolism control].
Fernández-García JC; Colomo N; Tinahones FJ
Med Clin (Barc); 2014; 143 Suppl 2():18-22. PubMed ID: 25326839
[TBL] [Abstract][Full Text] [Related]
54. The cardiovascular effects of glucagon-like peptide-1 receptor agonists: a trial sequential analysis of randomized controlled trials.
Wu S; Sun F; Zhang Y; Yang Z; Hong T; Chen Y; Zhan S
J Clin Pharm Ther; 2014 Feb; 39(1):7-13. PubMed ID: 24127768
[TBL] [Abstract][Full Text] [Related]
55. Glucagon-like peptide-1 receptor agonists and atrial fibrillation: a systematic review and meta-analysis of randomised controlled trials.
Monami M; Nreu B; Scatena A; Giannini S; Andreozzi F; Sesti G; Mannucci E
J Endocrinol Invest; 2017 Nov; 40(11):1251-1258. PubMed ID: 28569363
[TBL] [Abstract][Full Text] [Related]
56. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
[TBL] [Abstract][Full Text] [Related]
57. Use of Glucagon-Like-Peptide 1 Receptor Agonists and Risk of Fracture as Compared to Use of Other Anti-hyperglycemic Drugs.
Driessen JH; van Onzenoort HA; Starup-Linde J; Henry R; Burden AM; Neef C; van den Bergh JP; Vestergaard P; de Vries F
Calcif Tissue Int; 2015 Nov; 97(5):506-15. PubMed ID: 26184119
[TBL] [Abstract][Full Text] [Related]
58. Cardiovascular safety and benefits of GLP-1 receptor agonists.
Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
[TBL] [Abstract][Full Text] [Related]
59. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
Tzefos M; Harris K; Brackett A
Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
[TBL] [Abstract][Full Text] [Related]
60. Network meta-analysis of the risk of dyspepsia and anorexia in patients with type 2 diabetes mellitus induced by glucagon-like peptide 1 receptor agonist hypoglycemic drugs.
Jiao BL; Zhao J; Wang B; Liu BY; Wu T
Eur Rev Med Pharmacol Sci; 2024 Apr; 28(8):3073-3084. PubMed ID: 38708466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
